Chapters‎ > ‎Philadelphia‎ > ‎Events Philly Chapter‎ > ‎

LRIG Philly Scientific Meeting April 2017

posted Feb 2, 2017, 10:52 AM by Rodney Bednar   [ updated Apr 24, 2017, 9:23 AM ]
http://lrig.us8.list-manage.com/track/click?u=12255fe4385eeae677380eb71&id=7ab1aa8f96&e=5809e4c2f2

Tuesday April 25, 2017  (4:30 PM to 9:00 PM)  
Philly LRIG Spring Scientific Meeting 
DoubleTree by Hilton Philadelphia-Valley Forge 
301 West Dekalb Pike, 
King of Prussia, PA 19406 

Tentative Schedule:
4:30-6:00 PM   Free Food, Drinks, Dessert and Networking  
5:30                 Student Robotics Sponsorship and Mentor Program
                        Meet & Greet This Years Awardee
6:00-8:00 PM   Speakers
8:00-9:00 PM   Awards & Networking



LRIG - Philadelphia Chapter

Scientific Meeting – Spring 2017


Free Delicious Food served until 6:00pm!

  • Domestic and International Cheese Display
    • ... with dried fruit and nuts, assorted Crackers and flatbreads. Marinated Grilled Vegetables, Sundried Tomatoes, Mushrooms, Sweet Red Peppers, Olives, Artichoke Hearts, Eggplant and Zucchini, with Sweet Balsamic Glaze.
  • Pasta Station
    • ... with Rigatoni, Asparagus, and Sundried Tomatoes, Shitake Mushroomsand White Wine Sauce. Penne Pasta, Smoked Chicken and Garlic Cream Sauce
  • Butler Passed Hors D'Oeuvres
    • ... including Vegetable Spring Rolls, Scallops Wrapped in Bacon, Spinach and Feta Cheese in Filo Crust, Chicken Satay and Chilled Bay Shrimp with lemons and Cocktail Dipping Sauce
  • Roasted Pork Loin
    • ... with Mango Barbecue Sauce dinner rolls with assorted condiments
  • Freshly baked still warm Chocolate Chip Cookies
    • ...with Coffee, Tea, Soda and Water
       


Advances in Cell-Based Assays for Drug Discovery

 We are proud to offer an exciting program of presentations from leading experts in cell biology, screening and drug discovery. The event offers a unique opportunity for scientist from industry and academia to come together with local technology providers and automation experts to network, share ideas and collaborate.


SPEAKERS

Potential leads from High Throughput Screening (HTS) based drug discovery approaches often result in a high lead attrition rate, in part due to lack of disease relevant in vitro cellular models and predictive assay technologies. Recent developments in phenotypic screening using disease relevant cellular models and advanced assay technologies have reduced attrition rate and improved in vitro to in vivo connectivity.  Several examples will be presented to illustrate how phenotypic screening could accelerate lead discovery and drug repositioning.


6:00       
Evaluation of Axiogenesis Peri4U Induced Pluripotent Stem Cell-Derived Peripheral Neurons

Michael Finley, Ph.D.

Cell-based HTS, Lead Discovery, Janssen R&D

Human induced pluripotent stem cells (iPSCs) have the potential to bridge early stage drug discovery and human biology by providing access to relevant human cell types in quantities that are amenable to robust in vitro assay development.  Identifying a source of large numbers of more uniform human neurons for neuropathic pain indications has been a particular challenge; however, the Peri4U iPS derived peripheral neuron cell line was recently developed and commercialized by Axiogenesis using the Yamanaka factors.  We evaluated the Peri4U cells as a potential source of pain-sensing peripheral neurons by 1) determining whether Peri4U cells expressed common targets known to be expressed in small-diameter, pain-sensing neurons derived from dorsal root ganglia (DRG) via immunofluorescence and gene expression and 2) assessing Peri4U cells for neuron-like function such as neurite outgrowth and electrophysiological properties and 3) comparing transcriptome wide gene expression in differentiated and undifferentiated Peri4U cells to that of mature human DRG, brain and non-neuronal liver tissue.


6:30       
Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient

Donna Cartledge, Ph.D., Researcher, 

High-Throughput Screening and Drug Discovery Lab, Nemours Center for Childhood Cancer Research

Embryonal rhabdomyosarcoma (ERMS) is the most common pediatric soft tissue sarcoma, and its incidence is significantly increased in children with Costello syndrome (CS), a rare genetic disorder resulting from heterozygous germline mutations in the proto-oncogene HRAS. CS patients suffer from a very high 10% incidence of ERMS. The incomplete success to date of treating CS-derived ERMS patients highlights a need for better therapeutic options. As tools to discover targeted therapeutic leads, a CS patient-derived ERMS cell line (CS242 ERMS) harboring a homozygous p.G12A mutation in HRAS, and a control cell line derived from the same patient comprising non-malignant CS242 fibroblasts with a heterozygous p.G12A HRAS mutation were investigated. In a pilot study, a library of 2,000 compounds with known pharmacological activities was screened for their effect on CS242 ERMS cell viability. Follow-up testing in a panel of cell lines revealed that various compounds originally developed for other indications were remarkably selective; notably, the phosphodiesterase (PDE) inhibitor zardaverine was at least 1,000-fold more potent in CS242 ERMS than in the patient-matched non-malignant CS242 fibroblasts, other ERMS, or normal fibroblasts. Chronic treatment with zardaverine led to the emergence of resistant cells, consistent with CS242 ERMS comprising a mixed population of cells. In this presentation, I will describe characterization of the activity and selectivity of this compound, and initial studies to provide clues as to mechanism of action.


7:00       
A Case Study of Applying Annotated Chemical Libraries and Chemical Biology Strategies in Phenotypic Screens

Zining Wu, Ph.D.

Screening, Profiling & Mechanistic Biology, GSK


Sickle cell disease (SCD) is one of the most common genetic diseases and a major source of morbidity and mortality worldwide. Increasing fetal hemoglobin (HbF) has long been a therapeutic goal in management of SCD. This presentation will cover the strategy and outcome of phenotypic screens for HbF inducers. I will discuss the importance of setting up physiologically relevant cellular models in hit identification, the challenges and learning from screens using primary human cells and high-content data handling and analysis. The value of using annotated chemical libraries in phenotypic screening and the discovery of novel chemical modulators will also be presented.


7:30       
Phenotypic Screening to Accelerate Lead Discovery and Drug Repositioning

Zhuyin (Julie) Li, Ph. D.

Translational Biomarker, Lead Discovery & Optimization, BMS


Date: April 254:30-9:00 pm


Location:  DoubleTree by Hilton Philadelphia-Valley Forge 

                301 West Dekalb Pike, 
                King of Prussia, PA 19406 
                www.doubletreehotelvalleyforge.com

 

For the event details and updates go to

http://www.lrig.org/chapters/philadelphia

 

Contact Marina Nelen at marina.nelen@lrig.org


Comments